Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults

New England Journal of Medicine

Volumn 341, Issue 25, 1999, Pages 1865-1873

  Staszewski, Schlomo ^a   Morales Ramirez, Javier ^b   Tashima, Karen T ^c   Rachlis, Anita ^d   Skiest, Daniel ^e   Stanford, James ^f   Stryker, Richard ^g   Johnson, Philip ^h   Labriola, Dominic F ⁱ   Farina, Dianne ⁱ   Manion, Douglas J ⁱ   Ruiz, Nancy M ⁱ  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Clinical Research Puerto Rico Inc   (Puerto Rico)

^c MIRIAM HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^g Pacific Oaks Medical Group   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; ZIDOVUDINE;

EID: 0033576816     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199912163412501     Document Type: Article

References (45)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
4. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine: AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-7.
5. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
6. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
7. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
8. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998;13:586-93.
9. Katzenstein DA. Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care 1997;8:Suppl:10-7.
10. Van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997;17:774-8.
11. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996;45:921-5.
12. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69.
13. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42:332-8. [Erratum, Antimicrob Agents Chemother 1998;42:1308.]
14. Sutherland SE, Reigle MD, Seftel AD, Resnick MI. Protease inhibitors and urolithiasis. J Urol 1997;158:31-3.
15. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998;12:F167-F173.
16. Striker R, Conlin D, Marx M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998;27:218-20.
17. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27:65-7.
18. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
19. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12:1645-51.
20. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38: 153-79.
21. Kilby JM, Saag MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect Agents Dis 1994;3:313-23.
22. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
23. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998;27:1321-2.
24. Demeter LM, Meehan PM, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:136-44.
25. de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-70.
26. Carr A, Vella S, de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996;10:635-41.
27. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;15:1019-30.
28. Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:11-9.
29. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial: Italy, the Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
30. Division of Cancer Treatment. Guidelines for reporting adverse drug reactions. Washington, D.C.: National Cancer Institute, January 1988.
31. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
32. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
33. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
34. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70. [Erratum, Science 1997;275:14.]
35. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. J Int Assoc Physicians AIDS Care 1998;5:Suppl 2:4-33.
36. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998;36:2964-9.
37. Segondy M, Izopet J, Pellegrin I, et al. Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. J Clin Microbiol 1998;36:3392-5.
38. Hashida S, Hashinaka K, Nishikata I, et al. Shortening of the window period in diagnosis of HIV-1 infection by simultaneous detection of p24 antigen and antibody IgG to p17 and reverse transcriptase in serum with ultrasensitive enzyme immunoassay. J Virol Methods 1996;62:4-53.
39. Kempf D, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-F14.
40. Chene G, Morlat P, Leport C, et al. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. Control Clin Trials 1998;19:233-48.
41. Kleinman KP, Ibrahim JG, Laird NM. A Bayesian framework for intent-to-treat analysis with missing data. Biometrics 1998;54:265-78.
42. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996;52:1324-33.
43. Tsiatis A. Methodological issues in AIDS clinical trials: intent-to-treat analysis. J Acquir Immune Defic Syndr 1990;3:Suppl 2:S120-S123.
44. Youle M, Sawyer W. Reasons for discontinuation of antiretroviral treatment: a clinical survey. AIDS 1999;12:Suppl 4:S63. abstract.
45. Erickson-Viitanen S, Corbett J, Ko S, et al. DMP 961 and DMP 963: 2nd generation non-nucleosidc reverse transcriptase inhibitors active against the RT K103N mutant. In: Conference record of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4,1999. abstract.